JND Cover

Journal of Neuromuscular Diseases Transitioning to Gold Open Access in 2023

Amsterdam, April 13, 2023 – The Journal of Neuromuscular Diseases (JND), published by IOS Press, is pleased to announce that from July 1, 2023 (Volume 10, Issue 4), the journal will transition to a Gold Open Access publication. This means that all articles published after that date will be immediately and permanently freely available online for readers to view, download, share, and reuse, and will enable authors to more easily comply with funder and institutional mandates.

“When JND launched almost 10 years ago, among our primary goals was and continues to be the widespread dissemination of scientific and clinical knowledge to advance neuromuscular disease (NMD) research and benefit patients’ quality of life and outcomes,” explained co-Editors-in-Chief Carsten G. Bönnemann, MD, and Hanns Lochmüller, MD, PhD. “Therefore, we are extremely happy to support the next step in the journal’s evolution: migration to a fully open access publication model.”

With a strong Journal Impact Factor of 4.693* and Cite Score of 5.5**, JND is now recognized as one of the most influential journals in the world devoted exclusively to NMD. In recent years the number of open access papers published in JND has been steadily increasing, so that now approximately half are publicly available. The transition to fully open content will increase the journal’s impact and benefit the entire NMD community, including authors, readers, libraries, hospitals, funding agencies – and ultimately patients and their families.

JND offers a rigorous peer-review process and operates with rapid manuscript processing times. Accepted papers submitted from May 1, 2023, will be published Open Access under a Creative Commons license, and authors will retain copyright to their published work. It should be emphasized that the move to Open Access does not interfere with the editorial process, and the editorial office retains its independent right to accept and decline submitted papers based on their merit and quality.

The associated Open Access fee of $1,500 per accepted article has been set to be extremely competitive compared to those set by other journals in the field. The fee will not apply to certain publication types, like invited articles, editorials, and letters. Fees may be waived under certain circumstances, particularly from low-income countries as defined by Research4Life, upon application from the authors.

“The migration of the Journal of Neuromuscular Diseases to Gold Open Access is part of a very exciting time for us at IOS Press,” noted Publisher Rasjel van der Holst. “We are supportive of exploring new options facilitated by an evolving open access publishing landscape and meeting the growing expectations related to open access. JND joins our expanding portfolio of open content journals and books.”

Instructions for authors can be found here.

*Journal Citation Reports (Clarivate, 2022)
**Scopus CiteScore (2021)


For additional information, contact Rasjel van der Holst, IOS Press (r.holst@iospress.com).

The Journal of Neuromuscular Diseases aims to facilitate progress in understanding the molecular genetics/correlates, pathogenesis, pharmacology, diagnosis and treatment of acquired and genetic neuromuscular diseases (including muscular dystrophy, myasthenia gravis, spinal muscular atrophy, neuropathies, myopathies, myotonias and myositis). The journal publishes research reports, reviews, short communications, letters-to-the-editor, and will consider research that has negative findings. The journal is dedicated to providing an open forum for original research in basic science, translational and clinical research that will improve our fundamental understanding and lead to effective treatments of neuromuscular diseases. JND has a 2021 Journal Impact Factor of 4.693 according to Journal Citation Reports (Clarivate, 2022) and is published by IOS Press. www.iospress.com/journal-of-neuromuscular-diseases 

IOS Press is an independent international scientific, technical, medical (STM) publishing house established in 1987 in Amsterdam. We produce around 90 journals and 70 books annually in a broad range of subject categories, primarily specializing in health and life sciences (including neurosciences, medical informatics, cancer research, and rehabilitation) and computer sciences (including artificial intelligence, data science, and semantic web). In addition, we offer specialized services that support scientific advancement. www.iospress.com